Trial Profile
An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bertilimumab (Primary)
- Indications Bullous pemphigoid
- Focus Adverse reactions; Proof of concept
- Sponsors Immune Pharmaceuticals Inc
- 23 May 2018 According to an Immune Pharmaceuticals media release, pharmacokinetic and pharmacodynamic data from BP-01 study in Q3 2018.
- 21 May 2018 Status changed from recruiting to completed.
- 16 May 2018 According to an Immune Pharmaceuticals media release, updated results are being presented at the pre-IID Pemphigus and Pemphigoid Symposium.